151 results about "Arginase" patented technology

The invention discloses sgRNA for promoting development of cotton lateral root, a target sequence of sgRNA is respectively composed of the nucleotide sequences shown in SEQ ID No.1 or SEQ ID No.2, and two target sequences can be used by combination. The expression of cotton argininase gene can be inhibited through a CRISPR / Cas9 gene editing system. Compared with wild type plants, the lateral root number of the gene editing plants obtained by silencing the cotton argininase gene is obviously increased, the root surface area is obviously increased, No content is increased, absorption and utilization of nitrogen element and other nutrients by cotton are increased, and sgRNA has important meaning for increasing the cotton fiber output and quality as well as increasing the cotton stress resistance.

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.

The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.

A method for treating hepatitis by use of polyethanediol modified human arginase I, and its application are disclosed.

The invention provides a strain for producing ornithine and a method for biologically synthesizing ornithine with the same, belonging to the food biotechnology field. The strain and the method have the following beneficial effects: the invention relates to rummeliibacillus pycnus (SK23-002) screened from the soil; the collection number of rummeliibacillus pycnus is CCTCC NO:M2011466; the sporeformer is taken as the fermentation strain, glucose is taken as the carbon source and yeast cream and peptone are taken as nitrogen sources to form a fermentation medium to ferment ornithine or a thalluscontaining arginase, and the thallus is added to 5-20% of arginine solution to synthesize ornithine through transformation; through detection, the transformation rate can be more than 80%; the fermentation process can be independent of arginine induction; ornithine produced by the method is safe and reliable, is a functional product with great market potential and is widely applied to such industries as food, cosmetics, medicines and the like; and the method can be used for efficiently producing ornithine and is suitable for large scale production.

The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.